$0.63
+0.03 (+4.16%)
Open$0.60
Previous Close$0.60
Day High$0.63
Day Low$0.59
52W High$2.44
52W Low$0.42
Volume—
Avg Volume237.8K
Market Cap26.14M
P/E Ratio—
EPS$-0.16
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+6,928.8% upside
Current
$0.63
$0.63
Target
$44.00
$44.00
$29.80
$44.00 avg
$55.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.74M | 5.58M | 6.05M |
| Net Income | 1.11M | 1.28M | 1.11M |
| Profit Margin | 19.3% | 22.9% | 18.3% |
| EBITDA | 2.54M | 2.28M | 2.52M |
| Free Cash Flow | 874.9K | 1.03M | 1.03M |
| Rev Growth | +19.1% | +13.5% | +5.7% |
| Debt/Equity | 1.60 | 1.67 | 1.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |